Aligos Therapeutics Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Aligos Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $56.29. The average 1-year stock price forecast is 1,046.44% higher than the current stock price, while the lowest is $20 (+307.33%) and the highest is $175 (+3,464.15%).

Price Target: $56.29 (+1,046.44%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$20	$56.29	$45	$175
Change	+307.33%	+1046.4%	+816.50%	+3464.2%

Analyst Ratings

The average analyst rating for Aligos Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	3	4	4	4	6	6
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	5	5	5	7	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Daniel Brims Lake Street	Lake Street	Buy Maintains $45	Buy	Maintains	$45	+816.50%	Jun 1, 2026
Steven Seedhouse Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $20	Buy	Maintains	$20	+307.33%	May 29, 2026
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $50	Buy	Reiterates	$50	+918.33%	May 28, 2026
Yasmeen Rahimi Piper Sandler	Piper Sandler	Buy Maintains $175	Buy	Maintains	$175	+3,464.15%	May 8, 2026
Anthea Li Jefferies	Jefferies	Buy Initiates $48	Buy	Initiates	$48	+877.60%	Mar 19, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

21.68M

from 2.19M

891.61%

from 2.19M

Revenue Next Year

5.00M

from 21.68M

-76.93%

from 21.68M

EPS This Year

-7.11

from -2.45

EPS Next Year

-4.00

from -7.11

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	4.36M	13.91M	15.53M	3.95M	2.19M	21.68M
Revenue Growth	-	219.04%	11.66%	-74.60%	-44.59%	891.61%
Operating Income	-128.32M	-97.58M	-87.40M	-89.15M	-87.99M	-100.60M
Net Income	-128.33M	-96.05M	-87.68M	-131.21M	-24.19M	-93.95M
EPS	-	-	-	-	-2.45	-7.11
Free Cash Flow	-62.76M	-43.65M	-45.91M	-48.58M	-50.04M	-86.75M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	36.8M
Avg	21.7M
Low	2.8M

Revenue Growth

Revenue Growth	2026	2027	2028
High	1,584.8%
Avg	891.6%
Low	29.5%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-7.11
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-